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ABSTRACT
Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized 
by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), 
suggesting that it may be effectively targeted using MDM2 inhibitors. In the present 
study, we investigated the anticancer activity of the MDM2 inhibitors Nutlin 3a (in vitro) 
and RG7112 (in vivo), as single agents or in combination with rhTRAIL.  
In vitro studies were performed using MPM cell lines derived from epithelioid 
(ZL55, M14K), biphasic (MSTO211H) and sarcomatoid (ZL34) MPMs. In vivo studies 
were conducted on a sarcomatoid MPM mouse model. 
In all the cell lines tested (with the exception of ZL55, which carries a biallelic 
loss-of-function mutation of p53), Nutlin 3a enhanced p21, MDM2 and DR5 expression, 
and decreased survivin expression. These changes were associated to cell cycle arrest 
but not to a significant induction of apoptosis. A synergistic pro-apoptotic effect was 
obtained through the association of rhTRAIL in all the cell lines harboring functional 
p53. This synergistic interaction of MDM2 inhibitor and TRAIL agonist was confirmed 
using a mouse preclinical model. Our results suggest that the combined targeting 
of MDM2 and TRAIL might provide a novel therapeutic option for treatment of MPM 
patients, particularly in the case of sarcomatoid MPM with MDM2 overexpression and 
functional inactivation of wild-type p53.
INTRODUCTION
Malignant Pleural Mesothelioma (MPM) is a rare 
cancer with poor prognosis and increasing incidence [1]. 
The sarcomatoid (16%) and biphasic (34%) histologic 
subtypes are characterized by a worse prognosis compared 
to epithelioid MPM (50%) [2].
Surgery is feasible in few selected patients, and 
current systemic chemotherapy does not yield satisfactory 
results. Standard chemotherapy with a platinum-based 
doublet plus an antifolate drug achieves median overall 
survival (OS) and progression free survival (PFS) of about 
12 and 6 months, respectively [3, 4]. The lack of effective 
second line treatments and the failure of targeted therapies 
reinforce the need for new molecular targets and drugs for 
MPM treatment.
The molecular pathogenesis of MPM is 
characterized by frequent deletion of the INK4A/ARF 
locus (70–80%), which encodes p14/ARF and p16/INK4A, 
while p53 is not mutated in the majority of the cases [5, 6]. 
p14/ARF, an inhibitor of Murine Double Minute 2 
(MDM2), is crucial in the control of cell proliferation [7]. 
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In unstressed cells MDM2 and MDMX (also known as 
MDM4) keep p53 expression at very low levels through 
different mechanisms which include ubiquitylation and 
proteasomal degradation [8]. MDM2 expression is, in 
turn, enhanced by p53, thus creating a powerful negative 
feedback loop [9]. In the absence of genetic alteration, 
p53 function may be lost as a consequence of MDM2 
or MDMX overexpression, an alteration that is present 
in several solid and hematological tumors and correlates 
with poor prognosis and resistance to therapy [10, 11]. 
MDM2 overexpression and p53 mutations thus seem to be 
mutually exclusive, while tumors overexpressing MDMX 
may also carry inactivated p53 [12]. In addition, MDM2 
and MDMX may affect proliferation, angiogenesis, 
and DNA repair through p53-independent mechanisms 
[7, 12, 13]. To date, several MDM2 inhibitors have 
been tested in preclinical studies and in clinical trials. 
Among these, the most studied are Nutlin 3a and its 
analog, specifically designed for clinical use, RG7112 
(RO5045337, Roche, Basel, Switzerland). p53 reactivation 
by MDM2 inhibitors sensitizes p53 wild-type cancer 
cells to DNA damaging agents, which trigger the intrinsic 
pathway of apoptosis, or to extrinsic apoptosis activators 
such as TRAIL (Tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand) [14–17]. Nutlin 3a and RG7112 
are particularly effective in cancer cells overexpressing 
MDM2, while they are ineffective in cancer cells with 
downstream defects in the p53 pathway [18] or in cells 
overexpressing MDMX [19]. MDM2 overexpression has 
been previously reported in MPM samples, especially in the 
sarcomatoid and biphasic subtypes [20, 21], where it might 
represent a promising therapeutic target.
Building on these findings, in the present study we 
investigated the combination of rhTRAIL and Nutlin 3a 
or RG7112, in p53 wild type MPM cells, in vitro and in a 
preclinical MPM model.
RESULTS
p53 status and MDM2 expression in MPM cell 
lines
Mutational analysis of p53 in the MPM cell lines 
revealed a missense mutation in exon 7 (c.725G>A) 
associated with loss of heterozygosity (LOH) in ZL55 cells, 
M14K cells carried a monoallelic frameshift mutation in exon 
5 (c.406delC), while MSTO 211H and ZL34 were not mutated 
(Table 1). Based on the IARC and Cosmic database (http://
www.iarc.fr; http://cancer.sanger.ac.uk/cosmic), the 725G>A 
mutation causes loss of function of p53 and the 406delC, 
by inducing a frameshift, results in a premature stop codon 
located in exon 5 and in the expression of a truncated protein. 
qRT-PCR and immunoblot analysis revealed that MDM2 
mRNA and protein levels, were higher in the ZL34 cell line, 
which carries a wild-type p53 (Supplementary Figure 1A).
Nutlin 3a activates p53 and induces cell cycle 
arrest in MPM cell lines
We next analyzed the effects of Nutlin 3a on the 
expression of MDM2 and p21, two p53 transcriptional 
targets. Although p53 accumulation occurred in all the 
MPM cell lines upon treatment with Nutlin 3a, a dose 
dependent induction of p21 and MDM2 was detected in 
M14K, MSTO211H and ZL34 cells (p53 WT), but not 
in ZL55 cells (p53 -/-) (Figure 1A). Furthermore, DNA 
binding assays showed a strong increase in p53 binding to 
its target DNA in M14K, MSTO211H and ZL34 (but not 
ZL55) cell lines (Figure 1B). 
Consistent with a p53-dependent induction of p21, 
Nutlin 3a induced an accumulation in the G1 phase of the 
cell cycle in M14K, MSTO211H and ZL34 cells, but not 
in ZL55 (Figure 1C). 
Nutlin 3a synergizes with rhTRAIL in MPM cell 
lines
Although inducing cell cycle arrest, Nutlin 3a 
induced only a modest increase in cell death of the 
MPM cell lines (Figure 1D). Since it was previously 
reported that p53 activation increases TRAIL induced 
apoptosis [15], we tested the effects of Nutlin 3a plus 
rhTRAIL in the p53 wild-type MPM cell lines. As 
expected, the combined treatment of Nutlin 3a and 
rhTRAIL resulted in a significant increase of Specific 
Cell Death (both Annexin V/PI double positive cells) 
(Figure 2A). Moreover, time course experiments 
showed a strong increase of the Specific Cell Death 
over time in ZL34 cells, but not in ZL55 cells 
(Supplementary Figure 2).
Isobologram analysis using the Chou and Talalay 
equation [22] revealed that the association of Nutlin 3a 
and rhTRAIL was strongly synergistic in M14K, MSTO 
211H and ZL34 cells with a combination index (CI) < 1 
(Figure 2B and Supplementary Figure 1B). 
The synergistic interaction of Nutlin 3a and TRAIL 
is likely to result from the bidirectional connections 
between TRAIL and p53. TRAIL can engage the 
mitochondrial/intrinsic apoptotic pathway through 
caspase-8-mediated cleavage of Bid [23], and p53 may 
enhance responsivity to TRAIL by increasing DR5 
transcription [16, 17, 24–26] and decreasing survivin 
expression [15]. Consistent with these findings, our results 
showed that Nutlin 3a increased DR5 and decreased 
survivin expression in M14K, MSTO211H and ZL34 cells 
(Figure 3A, 3B). Consistent with this notion, when these 
MPM cells harbouring functional p53 were treated with 
Nutlin 3a and rhTRAIL, we observed a strong induction 
of cell death that was abrogated by treatment with the pan-
caspase inhibitor zVAD-fmk (Figure 4), indicating that the 
apoptotic pathway was engaged. 
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Antitumor activity of RG7112 plus rhTRAIL  
in vivo
The anticancer activity of MDM2 inhibition plus 
rhTRAIL treatment was tested  in vivo  by inoculating 
ZL34 cells intraperitoneally (IP) into SCID male mice. 
As Nutlin 3a is not suitable for clinical use because of 
its pharmacokinetics properties, we used its analogue 
RG7112, which is specifically formulated for clinical use. 
RG7112 efficiently inhibited MDM2-p53 binding and 
showed good pharmacological features [18].
ZL34 were selected as a preclinical model on the 
basis of their higher MDM2 expression and stronger 
synergistic response to the Nutlin 3a and rhTRAIL 
combination in vitro. The cells were engineered with a 
lentiviral vector encoding the luciferase gene (ZL34-LUC) 
to allow non invasive tracking of tumor growth in vivo. 
RG7112 and rhTRAIL were administered as depicted in 
the treatment schedule shown in Figure 5. 
Results showed a significant (p < 0,05) reduction of 
tumor growth in the RGT (RG7112 plus rhTRAIL) groups 
compared to mock-treated at the 15th and 22th days time 
Table 1: p53 status in MPM cell lines
MPM Cell Lines Histology TP53 Status Nucleotide change AA Mutation TA Class
ZL55 Epithelioid Mutated c. 725G>A (exon 7) p.C242Y(substitution-Missense) Non Functional
M14K Epithelioid Mutated(monoallelic) c.406delC (Exon 5)
p.Q136fs*34
(Deletion-Frameshift) Unknown
MSTO211H Biphasic Wild Type - -
ZL34 Sarcomatoid Wild Type - -
Figure 1: Nutlin 3a activity in p53 wild type and p53 mutated MPM cell lines. (A) Western blot analysis to detect MDM2, 
p53, p21 and β actin in MPM cell lines treated with DMSO or Nutlin 3a (N) (5 and 10 µM) for 24 hours. The figure is representative of two 
independent experiments. (B) p53 binding assay carried out using  nuclear extracts of MPM cell lines  treated with DMSO or Nutlin 3a 10 µM 
for 24 hours. Bar graph represents mean ± SD of the OD450 nm adsorbance values of two independent experiments (each run in duplicate). 
(C) Cell Cycle analysis of MPM cell by DNA content measurement using propidium iodide staining and flow cytometry. Cells were treated 
with DMSO or Nutlin 3a 10 µM for 24 hours. The graph represents the mean of the percentage of cells in each phase of the cell cycle of three 
different experiments (each run in duplicate). The asterisk indicates statistically significant (p < 0.05) differences of the percentage of cells in 
G1 phase between mock-treated (DMSO) and Nutlin 3a-treated MPM cells. p values were calculated using the  Mann-Whitney runk sum test. 
(D) Specific Cell Death of MPM cell lines treated with DMSO or Nutlin 3a 10 µM for 24, 48 and 72 hours. Results were represented as 
mean ± SD of two independent experiments, each run in duplicate. Specific Cell Death was calculated as detailed in Materials and Methods.
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points, while we observed no antitumor effect of RG7112 
and TRAIL administered as single agents.
DISCUSSION
Malignant Pleural Mesothelioma is a highly lethal 
disease, which is poorly responsive to current therapies 
[3, 4], particularly for the sarcomatoid subtype [27]. 
Clinical trials of biologic agents targeting key 
oncogenic pathways, such as phosphatidylinositol3-kinase 
(PI3K)/mammalian target of Rapamycin (mTOR), histone 
deacetylases (HDAC), Nuclear Factor kB (NFkB) and 
neoangiogenesis, did not achieve encouraging results and 
the systemic chemotherapy of MPM did not improve in 
the last 15 years. The lack of reliable biomarkers useful 
to select the patients more likely to benefit from specific 
treatments might, at least in part, explain these failures 
[28]. New therapeutic options and effective biomarkers 
for patient stratification/selection are thus in high demand. 
In recent years, small molecule inhibitors of MDM2 
or MDM2-p53 interaction have been investigated in 
several studies. Among these, the most studied are Nutlin 
3a and RG7112. Compared to Nutlin 3a, RG7112 is more 
suited for in vivo use as it is less sensitive to oxidation, has 
lower molecular weight, shows stronger MDM2 binding 
affinity and more favourable pharmacokinetic properties 
[18]. Clinical trials revealed a modest effectiveness of 
RG7112 in solid tumors, most of which carry wild-type 
p53 [29]. However, RG7112 showed promising activity 
in leukemias [30] and a more potent nutlin analog, 
RG7388 (idasanutlin) [31, 32], is under investigation for 
the treatment of relapsed/refractory AML in a phase 3 
Figure 2: Nutlin 3a synergizes with rh/TRAIL in apoptosis induction in MPM cell lines. (A) Biparametric Annexin V/
propidium iodide flow cytometry analysis to test apoptosis of MPM cell lines treated with 10 µM Nutlin 3a and/or 2.56 µM rhTRAIL (T) 
for 24 hours. A representative dot blot is shown (left panel). Results are represented as mean ± SE of three independent experiments run in 
triplicate (right panel). Asterisks indicate statistically significant differences between MPM cells treated with rhTRAIL compared with cells 
treated with Nutlin 3a plus rhTRAIL (*p < 0.05; **p < 0.005 and ***p < 0.001); p values were calculated using the Mann-Whitney runk 
sum test. (B) Isobologram analysis using the Chou-Talalay equation. MPM cell lines were treated for 24 hours with Nutlin 3a and rhTRAIL 
(3.9:1 ratio).  The synergistic effects of these drugs were assessed by calculating the Combination Index (CI) method (see Materials and 
Methods). Bar graph represents the mean ± SD of CI values at FA (fraction affected) 0.25, 0.5, 0.75 and 0.9. 
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trial (www.clinicaltrials.gov). A phase 1b clinical trial in 
sarcomas showed that the combination of RG7112 with 
doxorubicin produced significant haematological toxicity 
(increased neutropenia and thrombocytopenia) (Chawla 
SP et al., J Clin Oncol 31, 2013-abstr 10514). Drugs with 
a milder toxicity profile, such as rhTRAIL (Dulanermin) 
may thus be better suited for the association with MDM2 
inhibitors [33].
rhTRAIL is a member of the TNF ligand 
superfamily, able to selectively kill transformed cells. 
TRAIL acts by binding the TRAIL Death Receptors 1 and 
2 (DR4 and DR5) and activating both the extrinsic and the 
intrinsic apoptotic pathway. Although, several cancer cells 
show resistance to TRAIL [23], previous studies showed 
that DNA damaging agents or Nutlin 3a increased TRAIL 
mediated cell death through the increase of the TRAIL 
receptors expression  [24–26, 34, 35]. To date, no data are 
available about the in vivo efficacy of this combination.
We reasoned that MPM might be a good model 
to test this combination because of its frequent MDM2 
overexpression [20] and low rate of p53 mutation 
[36]. Importantly, higher expression levels of MDM2 
characterize sarcomatoid/biphasic compared to epithelioid 
MPM samples [21]. 
Consistent with previous data [37], in our study no 
p53 activity was detected in p53 mutated ZL55 upon Nutlin 
3a administration, while it was functional both in p53 WT 
cells (ZL34 and MSTO), and in M14K cell line harboring 
a monoallelic 406delC, thus suggesting that the other allele 
was sufficient to sustain p53 function (Figure 1A, 1B).
Nutlin 3a caused time-dependent induction of cell 
death in ZL34 and MSTO211H, but only minor effects 
in ZL55 and M14K cell line up to 72 hours of treatment 
(Figure 1D), probably because of higher expression of 
MDM2 and functional p53 in the first two cell lines.  
Interestingly, when Nutlin 3a and rhTRAIL were 
simultaneously administered in p53 wild type cells, a 
synergistic increase of cell death was detected after 24 
hours treatment (Figure 2). In p53-responsive MPM cells, 
Nutlin 3a induced DR5 expression, repression of survivin 
and increased apoptosis (Figures 3 and 4). The in vivo 
relevance of the combined actions of MDM2 inhibition 
and TRAIL agonists was tested using a xenograft mouse 
model that recapitulates sarcomatoid MPM with WT p53. 
Interestingly, our results demonstrated that RG7112 plus 
rhTRAIL significantly reduced tumor growth compared to 
the mock-treated group (Figure 5). 
Taken together our data suggest that MDM2 
inhibition plus TRAIL agonists may prove to be effective 
for MPM treatment, particularly (but not only) for 
non epithelioid MPM. p53 wild-type status and high 
expression levels of MDM2 could be critical to achieve 
a good response rate and so may represent important 
markers for patients’ selection.
Figure 3: Nutlin 3a treatment increases DR5 and decreases Survivin expression. (A) Flow cytometry analysis of DR5 
expression in MPM cell lines treated with Nutlin 3a 10 µM for 24 hours. Representative histogram plots are shown (upper panel). P values 
were calculated using the Kolmogorov-Smirnov Statistics. The bar graph (lower panel) represents the mean ± SE of relative expression 
(calculated as detailed in Materials and Methods) of DR5 of three independent experiments run in triplicate. Statistically significant 
differences of receptor expression between untreated (DMSO) MPM cells compared to MPM cells treated with Nutlin 3a were evaluated 
using the Mann-Whitney runk sum test (*p < 0.05; **p < 0.005). (B) Western Blot analysis for survivin expression of MPM cell lines 
treated with Nutlin 3a 10 µM for 24 hours. A representative immunoblot is shown (upper panel). Densitometry of survivin values were 
normalized on β-actin values and reported as percentage relative to control (DMSO-treated samples). Mean values ±SE of three independent 
experiments are shown (lower panel). 
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MATERIALS AND METHODS
Cell lines and reagents
We employed two MPM cell lines of epithelioid 
derivation (ZL55, M14K), one biphasic cell line 
(MSTO211H) and one sarcomatoid cell line (ZL34). ZL55 
and ZL34 cell lines were kindly supplied by Dr, E. Felley-
Bosco (University of Zurich, Switzerland); M14K and 
MSTO211H cell lines were kindly supplied by Prof. L. 
Willems (University of Liège, Belgium). All cell lines have 
been authenticated by STR profile. Analysis was performed 
by BMR Genomics S.R.L (Padova, Italy). Analysis of ZL34 
cell was performed on November 2015. Analysis of ZL55, 
M14K and MSTO211H was performed on February 2016. 
ZL55, ZL34 and MSTO211H cell lines displayed 96%, 
100% and 100% match with reference profiles (www.phe-
culturecollections.org.uk/; http://www.attc.org/) (evaluated 
by International Cell Line Authentication Committee 
– ICLAC- match criteria) (Supplementary Table 1).  No 
reference profile is available for M14K cells.
All MPM cell lines were maintained in Roswell 
Park Memorial Institute medium (RPMI) 1640 (Gibco-
Thermo Fisher Scientific, Waltham, Massachusetts, 
U.S.) supplemented with 2 mM L-glutamine, 1 mM 
sodium pyruvate, 10% FBS and 1% (w/v) penicillin/
streptomycin (Invitrogen- Thermo Fisher Scientific, 
Waltham, Massachusetts, U.S.). All cells were cultured 
at 37°C in a humidified atmosphere containing 5% CO2. 
Nutlin 3a, was purchased from Sigma- Aldrich (Sigma-
Aldrich St. Louis, MO, U.S.). RG7112 was supplied 
from Roche (Roche, Basel, Switzerland). rhTRAIL was 
supplied from Amgen/Genentech (Amgen Inc, Thousand 
Oaks, CA, U.S.; Genentech Inc, South San Francisco, CA, 
U.S.). Caspase Inhibitor I, zVAD-fmk, was purchased from 
Merck Millipore (Darmstadt, Germany). 
 p53 mutational analysis
In the COSMIC, Catalogue of Somatic Mutations 
in Cancer, nine mutations are reported for 147 analysed 
mesotheliomas, and exons 5, 7, 8, 10 were involved. The 
IARC, International Agency for Research on Cancer, dataset 
also reported 10 TP53 mutated cases in exon 5, 7 and 8. 
Therefore, TP53 mutations were investigated by analysing 
exons 4 to 10, where the majority of mutations are localized.
Briefly, DNA isolated from MPM cell lines was 
subjected to PCR using primer pairs specific for each exon 
Figure 4: Nutlin 3a synergism with rh/TRAIL involves increase of apoptosis. Apoptosis Assay of MPM cell lines treated 
with Nutlin 3a 10 µM and/or rhTRAIL (T) 2.56 µM for 24 hours, in presence or absence of 1 hour zVAD-fmk preincubation. Results are 
represented as mean ± SE of two independent experiments, each run in triplicate (right panel). Asterisks indicate statistically significant 
difference between Nutlin 3a plus rhTRAIL-treated cells in absence or presence of zVAD (p < 0.005) calculated using the Mann-Whitney 
runk sum test. In the left panel a representative dot blot is shown. 
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by the IARC protocol. The amplified products were then 
sequenced by fluorescent capillary electrophoresis (ABI 
PRISM 310 genetic analyzer, Applied Biosystems-Thermo 
Fisher Scientific, Waltham, Massachusetts, U.S.) and 
sequences were compared with NCBI Reference Sequence 
NC_000017.10.
Western blot
Cells were washed twice in ice-cold PBS (phosphate 
buffer saline), and lysed in Mammalian Cells Disruption 
Buffer Paris-Kit (Ambion- Thermo Fisher Scientific, 
Waltham, Massachusetts, U.S.) supplemented with 
Phosphatase Inhibitor Cocktail (Roche, Basel, Switzerland) 
and Complete Protease Inhibitor Cocktail (Roche, Basel, 
Switzerland). Protein concentration was determined by the 
Coomassie (Bradford) Protein Assay Kit (Thermo Fisher 
Scientific, Waltham, Massachusetts, U.S.) using bovine 
serum albumin as standard, and equal amounts of proteins 
were analyzed by SDS-PAGE (acrylamide/bis-acrylamide). 
Gels were electroblotted onto polyvinylidenedifluoride 
membranes (Amersham-GE HEALTHCARE Little 
Chalfont, Buckinghamshire, U.K.). In immunoblot 
analysis, membranes were blocked for 1 hour with 5% 
non-fat dry milk in Tris Buffered Saline (TBS) containing 
0.1% Tween-20, and incubated at 4°C over night with 
primary antibody direct against p53 (cat n°sc6243), MDM2 
(cat n°sc 965), (Santa Cruz Biotechnology, Dallas, Texas, 
U.S.),  p21 (cat n° 2946) (Cell Signaling Technology, 
Boston, MA, USA), survivin (cat n° ab76424) (ABCAM 
Cambridge, UK) and anti-β-actin antibody (cat n° A5060) 
(Sigma-Aldrich St. Louis, MO, U.S.) used as loading 
control, followed by horseradish peroxidase-conjugated 
secondary antibodies (Pierce-Thermo Fisher Scientific, 
Waltham, Massachusetts, U.S.). Finally, the membranes 
were incubated with chemiluminescence reagents (Lite 
Ablot Turbo; Euroclone, Milano, Italy) and revealed 
using UVITEC system (Uvitec, Cambridge, U.K.). 
Quantification of the bands was performed using UVITEC 
Image Quantification Software (Uvitec, Cambridge U.K.).
Figure 5: In vivo antitumor activity of RG7112 plus rhTRAIL in MPM xenograft mouse model. In vivo experiments were 
conducted using SCID mice injected IP with 5 × 106 ZL34-LUC. 4 weeks post injection mice were randomized in 4 treatment groups and 
treated with RG7112 (RG) or vehicle (V) (days 1–21) by gavage and/or rhTRAIL (T) (days 1–3)  IP (see schedule of treatment). Tumor 
size was assessed at the indicated time point by in vivo bioluminescence. Left panel shows luminescence of a representative mouse for each 
group. The mean ± SE of the ∆ Average radiance for each group at every time point of three independent experiments is shown in the graph. 
Asterisks indicate statistically significant differences of average radiance between treated groups and untreated controls (p < 0.05) using 
the one way ANOVA on ranks analysis followed by Dunn’s post hoc test.
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p53 DNA-binding activity
p53 DNA-binding activity was assayed using the 
TransAM p53 kit (Active Motif Inc, Carlsbad, CA, U.S.), 
according to the manufacturer’s instructions. Nuclear 
Extracts of MPM cells treated or not with Nutlin 3a 10 µM 
for 24 hours were used for the assay. p53 DNA binding was 
measured by colorimetric assay, and absorbance was read 
at 450 nm using Victor Microplate Reader (PerkinElmer 
Inc, Massachusetts, U.S.). Absorbance at 450 nm was 
proportional to p53 binding at the consensus DNA sequence. 
Cell cycle analysis
Cell cycle analysis was performed by flow cytometry 
detection of DNA content using Propidium iodide (PI) 
staining. MPM cells were treated with Nutlin 3a 10 µM. 
After 24 hours the cells were trypsinized, washed with 
PBS and fixed for 1 hour at –20°C in a following solution: 
RPMI (500 ml), FCS 10% (500 ml) and ice cold ethanol 
70% (3 ml). After two washes in PBS, the cells were 
incubated with PBS, PI (Sigma-Aldrich St. Louis, MO, 
U.S.) 100 mg/ml and RNase (Qiagen, Venlo, Netherlands) 
0,4 mg/ml for 1 hour at 37°C. PI staining was detected 
by FACSCalibur apparatus (BD Biosciences San Jose, 
CA, U.S.) and DNA content quantified using Modfit LT 
software (Verity, Topsham, Maine U.S).
Apoptosis assay and drugs combination assay
MPM cells were seeded into 12-well plates in 
1.0 mL/well of complete RPMI 1640 and treated with 
Nutlin 3a (10 µM) for 24, 48 and 72 hours and/or rhTRAIL 
2.56 µM for 24 hours. Apoptosis Assay was performed 
using Annexin-V-Fluos and PI staining (Roche, Basel, 
Switzerland) according to the manufacturers’ instructions. 
Cells were collected, centrifuged, and resuspended in 
300 µL of Annexin-binding buffer, followed by incubation 
with 1 µL of Annexin V-Fluos and 1µL of PI for 10 minutes 
at room temperature. Cells positive for Annexin V/PI were 
detected by flow cytometry using a FACSCalibur apparatus 
and analyzed using CellQuest software (BD Biosciences 
San Jose, CA, U.S.). Specific Cell Death was calculated 
by the following formula: (percentage of Annexin V or PI 
positive cells in treated samples- percentage of AnnexinV or 
PI positive cells in untreated samples)/(100- percentage of 
Annexin V or PI positive cells in untreated samples)* 100.
Drug Combination studies were conducted using the 
Chou-Talalay method [22]. MPM cell lines were treated 
for 24 hours with different concentration of Nutlin 3a 
and rhTRAIL (3.9:1 ratio) and Specific Cell Death was 
measured by PI staining.
The combination index (CI) was calculated using 
the CompuSyn software (ComboSyn, Inc., Paramus, NJ), 
where CI < 1, CI=1, and CI > 1 indicated synergistic, 
additive, and antagonistic effects, respectively.
DR5 expression levels quantification
Surface expression of DR5 TRAIL receptor was 
evaluated by indirect immunostaining using a specific 
DR5 primary antibody (cat n° AG-20B-0023) (Alexis 
Biochemicals, San Diego, CA, U.S.) followed by Alexa 
Fluor 488 Goat anti-mouse immunoglobulin G (IgG H+L) 
(Life Technologies-Thermo Fisher Scientific, Waltham, 
Massachusetts, U.S.). Flow cytometry analysis was 
performed using a FACSCalibur apparatus and CellQuest 
software (BD Biosciences San Jose, CA, U.S.). Relative 
expression of TRAIL-R was calculated by the following 
formula: percentage of positive cells x mean fluorescence 
intensity (MFI).
In vivo experiments
In vivo experiments were performed in accordance 
with the Padua University Ethic Committee for Animal 
Testing. 49 SCID male mice at the 6th week were 
intraperitoneally (IP) injected with 5 × 106 ZL34 cells 
previously transduced with lentiviral vector containing a 
plasmid encoding for Luciferase (ZL34-LUC). 4 weeks post 
injection mice were randomized in 4 treatment groups and 
treated with RG7112 (RG, 100 mg/Kg/die on days 1–21) 
or vehicle (V, 100 ml on days 1–21) by gavage and/or 
rhTRAIL (T, 60 mg/Kg/die on days 1–3) IP. rhTRAIL and 
RG7112 schedule and dose were established according to 
previous studies (data on file, Amgen Inc, CA/Genentech 
Inc, 2009 and [18]). Tumor size was assessed by in vivo 
bioluminescence using Xenogen bioluminescence imaging 
(IVIS, Xenogen, Alameda, CA, U.S.) after IP injection of 
D-luciferin (150 mg/Kg) in each mouse at the indicated 
time point. Mice were suppressed at the 22th day. Average 
Radiance [p/s/cm²/sr] was proportional to the number of 
ZL34-LUC cells.  ∆ Average radiance was used as indicator 
of tumor growth and calculated by the following formula: 
(Average Radiance at the day n- Average Radiance at the 
day 1)/Average radiance at the day 1. 
Statistical analysis
All data were analyzed using the SigmaPlot software, 
and results were expressed as means ± standard deviation 
(SD) or standard error (SE). To compare different groups 
of treatment, we use the non parametric Mann-Whitney 
runk sum test for in vitro studies and the Kruskal-Wallis 
H test (One way ANOVA on ranks) followed by Dunn’s 
post hoc test for in vivo studies. Difference was considered 
significant with a p value ≤ 0.05.
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